First published 9/30/2026, 7:59:15 AM · Last updated 9/30/2026, 7:59:15 AM

Circulating sMAdCAM-1 levels and α4β7+ tregs as indicators of gut-liver barrier impairment and predictors of treatment success in immunotherapy-treated advanced hepatobiliary cancers

A journal article reports that circulating sMAdCAM-1 levels and α4β7+ regulatory T cell levels indicate gut–liver barrier impairment and predict treatment success in immunotherapy-treated advanced hepatobiliary cancers. The item is published by Georg Thieme Verlag KG as a journal article on 2026-08-01.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 5/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 4/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 7/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

If validated, these biomarkers could help assess and predict immunotherapy response in advanced hepatobiliary cancer patients.

Sources

Circulating sMAdCAM-1 levels and α4β7+ tregs as indicators of gut-liver barrier impairment and predictors of treatment success in immunotherapy-treated advanced hepatobiliary cancers

Report an issue